Fractyl Health, Inc Common Stock

Yahoo Finance • 6 days ago

Fractyl Health stock gains after pricing of $60M underwritten offering

* Fractyl Health (NASDAQ:GUTS [https://seekingalpha.com/symbol/GUTS]) on Friday announced [https://seekingalpha.com/pr/20245642-fractyl-health-announces-pricing-of-60-million-underwritten-offering-of-common-stock] the pricing of an under... Full story

Yahoo Finance • 6 days ago

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics com... Full story

Yahoo Finance • 6 days ago

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regain in sham-treated patients Revita proc... Full story

Yahoo Finance • 29 days ago

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

BURLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diab... Full story

Yahoo Finance • 2 months ago

Canaccord Genuity lowers Fractyl Health stock price target to $6 from $12

Investing.com - Canaccord Genuity lowered its price target on Fractyl Health Inc (NASDAQ:GUTS) to $6.00 from $12.00 on Thursday, while maintaining a Buy rating on the stock. The company’s shares currently trade at $1.01, with InvestingPro... Full story

Yahoo Finance • 2 months ago

Fractyl Health Posts 62% Wider Q2 Loss

Key Points Net loss (GAAP) widened 62% to $27.9 million compared to Q2 2024, as research and development spending rose 26% over the prior year period. No revenue was reported this quarter, in line with expectations. Clinical programs adva... Full story

Yahoo Finance • 2 months ago

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 d... Full story

Yahoo Finance • 2 months ago

What's going on in today's session

Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SGBX [https://www.chartmill.com/stock/quote/SGBX/profile] 86.14% SAF... Full story

Yahoo Finance • 2 months ago

Here are the top movers in Wednesday's session.

Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TOP GAINERS TICKER CHANGE COMMENT GO [https://www.cha... Full story

Yahoo Finance • 2 months ago

The market is filled with gapping stocks in Wednesday's session.

Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. [gap] GAP UP STOCKS TICKER CHANGE COMMENT SGBX [https://www.chartmill.com/stock/quote/SGBX... Full story

Yahoo Finance • 2 months ago

Fractyl Health prices $20 million public offering of common stock

BURLINGTON, Mass. - Fractyl Health, Inc. (NASDAQ:GUTS), a metabolic therapeutics company focused on treatments for obesity and type 2 diabetes, announced Wednesday the pricing of its underwritten public offering of 19,047,619 shares of com... Full story

Yahoo Finance • 2 months ago

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering pattern-breaking approaches that treat root causes of obesity and type 2 d... Full story

Yahoo Finance • 2 months ago

Discover the top movers in Wednesday's pre-market session.

As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMME... Full story

Yahoo Finance • 2 months ago

Top movers in Tuesday's after hours session

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. [postmarket] GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 2 months ago

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Two-year follow-up in Germany Real-World Registry study showed median 9.6% weight loss and 1.6% HbA1c reduction after a single Revita procedure in participants with type 2 diabetes, with no device- or procedure-related serious adverse even... Full story

Yahoo Finance • 3 months ago

Canaccord Genuity reiterates Buy rating on Fractyl Health stock

Investing.com - Canaccord Genuity has reiterated its Buy rating and $12.00 price target on Fractyl Health Inc (NASDAQ:GUTS), currently trading at $1.79, following the company’s presentation of updated data from its Phase 3 trial of Revit... Full story

Yahoo Finance • 3 months ago

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure Median weight remained stable through 3 months (0.46% / ~ 1 pound weight chang... Full story

Yahoo Finance • 3 months ago

Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models

New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity Rejuva-treated healthy animals exposed to a high fat diet were protected from weight gain and hyperglycemia Data r... Full story

Yahoo Finance • 3 months ago

Fractyl Health receives two new patents for duodenal resurfacing tech

BURLINGTON, Mass. - Fractyl Health, Inc. (NASDAQ:GUTS), a clinical-stage medical technology company with a market capitalization of $95.5 million, has been granted two new U.S. patents that strengthen its intellectual property portfolio in... Full story

Yahoo Finance • 4 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

BURLINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D)... Full story